Medennium
This article was originally published in The Gray Sheet
Executive Summary
Novartis subsidiary Ciba Vision acquires an initial 10% equity stake in the ophthalmic product start-up. The move gives Ciba exclusive marketing and distribution rights to Medennium's PRL (phakic refractive lens), an intraocular lens designed for implantation into the posterior chamber of the eye to correct hyperopia and myopia. Phase II trials for the PRL are ongoing in the U.S., with Phase III studies slated to begin in early 2001, Ciba says. A CE mark is expected sometime in 2001
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.